A Phase 4 interventional study of Intravesical antibiotic instillation and Antibiotic oral suppressive therapy in Recurrent Urinary Tract Infection, sponsored by Atlantic Health System. Recruiting at 1 site in United States. Open to female participants. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Atlantic Health System · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 275 studies in Urinary Tract Infections with a site in United States — 44 open to participants now, 57 under way, 2 of them phase 3. Urinary Tract Infections · United States.
Among the 275 studies in Urinary Tract Infections with a site in United States, this one is the 112th largest by planned enrollment of the 225 interventional ones that give a count, is one of 12 that started in 2021, is one of 40 in phase 4, reaches primary completion later than 29 of the 56 other live ones, and was the 175th registered.
808 studies on the registry are indexed under Urinary Tract Infections; 135 are open to participants now.
Browse Urinary Tract Infections studies →44 of the 275 studies in Urinary Tract Infections with a site in United States are open now. Recruiting first, the newest first:
GlaxoSmithKline · Sites in United States
Ages 15–50 · Women only
University of Miami · Sites in United States
Ages 18+ · Women only
GlaxoSmithKline · Sites in United States
Ages 18–50 · Women only · Healthy volunteers
Megan Bradley · Sites in United States
Ages 65+ · Women only
Baylor College of Medicine · Sites in United States
Ages 0 mo–5 mo · Men only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 84 Urinary Tract Infections studies recruiting now, 51 (61%) set no upper age limit and 23 (27%) stop at 75 or younger; 17 take children under 18; 15 take healthy volunteers.
This study: female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
275 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 41 · Phase 3 33 · Phase 4 40
First in 1988; this study’s year is marked. 12 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 131 across 564 interventional studies indexed under Urinary Tract Infections.
Median enrollment 100 across the 225 interventional studies, 229 across the 50 observational. Of the 190 that completed or were terminated, 89 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
73 of 275 have an industry lead sponsor. The 10 most frequent:
Atlantic Health System is the lead sponsor of 64 studies on the registry; 12 are open to participants now.
Atlantic Health System has 2 studies filed under Urinary Tract Infections — fewer than ten, so there is no comparison to draw.
26 of the studies in Urinary Tract Infections with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07686055Phase 3Megan BradleyPrecision Management of Urinary Tract Symptoms in Older Women | 2027-02-01 |
| NCT07947108Good Kitty CoA Clinical Trial to Evaluate the Effects of a Supplement on Urinary Symptoms | 2026-12 |
| NCT06976125University Hospitals Cleveland Medical CenterApplication of a Prediction Model for Directing Antibiotic Use in the Treatment of Urinary Tract Infection in an Ambulatory Setting | 2026-12-01 |
| NCT07453693Bonafide HealthAn Efficacy Study of a Dietary Supplement Drink Mix for Urinary Health Improvement | 2026-12-15 |
| NCT07542834Ohio UniversityUsing Virtual Reality to Improve Medical Training | 2026-12-31 |
Add all 26 to your calendar (.ics) → With an account.
Among the 275 studies in Urinary Tract Infections with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a research study that aims to determine if antibiotic bladder instillations (placing an antibiotic directly into the bladder) over several sessions at the office is a good option to prevent recurrent urinary tract infections, in comparison with oral suppression therapy (taking daily antibiotics in the form of pills by mouth). Oral antibiotic suppression therapy is currently the most common treatment route for recurrent urinary tract infections in post-menopausal women. The bladder antibiotic instillation may overcome the disadvantages of oral suppression therapy such as antibiotic resistance, certain side effects, and recurrence of infections after finishing the treatment course.
In this study, the investigators aim to determine the effectiveness of intra-vesical antibiotic instillations for the prophylactic treatment of recurrent urinary tract infections in menopausal women in comparison with oral suppressive therapy. This is a parallel un-blinded randomized-controlled trial. the investigators will randomize post-menopausal women with recurrent urinary tract infections to either receive 6-8 intra-vesical antibiotic instillations at the office or to receive 3 months of oral antibiotic suppressive therapy.
In the bladder instillation arm, based on the participant's allergy and antibiotic resistance profile, one of the following three antibiotics will be instilled intravesically via a latex free BARD® 12 French Foley catheter for a total of 6-8 instillations (2 instillations/week) according to the Atlantic Health System Urogynecology Division antibiotic bladder instillation standard protocol:
In the antibiotic oral suppression therapy arm, one of the following routinely used antibiotics will be prescribed for a total of 3 months according to the American Urogynecology Society Guidelines and based on the participant's allergy and antibiotic resistance profile:
Participants will be followed for total of 3 months after finishing either treatment course by only reviewing their medical records to collect data regarding development of urinary tract infections after treatment.
Primary endpoint/outcome:
Secondary endpoints/outcomes:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Intravesical antibiotic instillation
Drug: Antibiotic oral suppressive therapy
Based on the participant's allergy and antibiotic resistance profile, one of the following three antibiotics will be instilled intravesically via a latex free BARD® 12 French Foley catheter for a total of 6-8 instillations (2 instillations/week) according to the Atlantic Health System Urogynecology Division antibiotic bladder instillation standard protocol: * Amikacin-30 mg in 60 ml of sterile water * Gentamycin-80mg in 60ml sterile water * Tobramycin-80 mg in 100 ml of sterile water
In the antibiotic oral suppression therapy arm, one of the following routinely used antibiotics will be prescribed for a total of 3 months according to the American Urogynecology Society Guidelines and based on the participant's allergy and antibiotic resistance profile: * Trimethoprim daily (100 mg) * Trimethoprim/sulfamethoxazole daily (40 mg/200 mg) * Trimethoprim/sulfamethoxazole every 3 days (40 mg/200 mg) * Nitrofurantoin monohydrate/macrocrystals daily (50 mg) * Nitrofurantoin monohydrate/macrocrystals daily (100 mg) * Cephalexin daily (125 mg) * Cephalexin daily (250 mg) * Fosfomycin every 10 days (3 grams)
The percentage of participants with urinary tract infections following treatment course
To compare the percentage of women developing urinary tract infections during the 3 months following treatment between the two groups.
Time frame: Assessed starting immediately after the treatment is completed for a total of 3 months.
The rate of antibiotic resistance of pathogens in participants developing urinary tract infections after completing the treatment course.
To compare the rate of antibiotic resistance of isolated pathogens when participants develop a urinary tract infection during the 3 months follow up period after intra-vesical antibiotic instillation vs. oral antibiotic suppressive therapy. the percentage of antibiotics on the susceptibility list of urine cultures will be compared between participants developing urinary tract infection in each group during the 3 months follow-up period after completing the treatment.
Time frame: Assessed starting immediately after the treatment is completed for a total of 3 months
the percentage of patients developing side effects of the 2 treatments
To compare the percentage of patients developing side effects between the two treatment modalities. At their routine follow up visits patients will be asked about whether or not they developed side effects and the type and severity of side effects of the treatment received. The percentage of patients developing side effects (per type and severity) in each arm will be compared.
Time frame: From the date of randomization until the date of first documented side effect assessed up to 3 months after the treatment is completed in each arm
Plan to share: No
Started Jun 2021 (actual). Primary completion is estimated for Jun 2027, 72 months after the start.
Of 45 non-industry phase 4 interventional studies under Urinary Tract Infections, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 54. This study's planned 72 months is above that.
Counting every sponsor, half of 51 studies reached it within 37 months; a quarter within 22 and three quarters within 50.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: start Mar 2021 → Jun 2021, primary completion Apr 2023 → Jun 2027 and completion Apr 2023 → Dec 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Atlantic Health System